PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29665297-2	2018	In this study, we examined the effects of the fast-acting, beta1 selective blocker esmolol on systemic hemodynamics and leg muscle O2 saturation (near infrared spectroscopy, NIRS) during submaximal leg ergometry.	esmolol	83-90	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	59-64	
31514219-3	2019	Therefore, heart rate control may be necessary to prevent cardiovascular events.Esmolol and landiolol as ultrashort and rapid acting highly selective beta 1 -adrenergic blockers are of particular interest in the prevention and management of cardiac arrhythmias.	esmolol	80-87	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	150-156	
27451411-2	2016	Esmolol was introduced some three decades ago as a short-acting beta1-selective antagonist.	esmolol	0-7	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	64-69	
28035016-7	2017	Collectively, our data indicate that infusion of ~160 mg of esmolol (range 110-200 mg in the 5 min before exercise) acutely and selectively blocks beta1-receptors in healthy humans.	esmolol	60-67	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	147-152	
28035016-10	2017	Collectively, our data indicate that infusion of ~160 mg of esmolol (range 110-200 mg in the 5 min before exercise) acutely and selectively blocks beta1-adrenergic receptors.	esmolol	60-67	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	147-152	
27451411-8	2016	If cells were incubated for >=24 hours in the presence of >=1 muM esmolol, the levels of beta1-adrenergic-but not of beta2-adrenergic-receptors increased.	esmolol	72-79	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	95-100	
19150530-12	2009	The ultra-short-acting beta-1 selective adrenergic antagonists esmolol and landiolol can be safely used perioperatively in patients with airway hyperreactivity.	esmolol	63-70	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	23-29	
26121122-9	2015	Five prospective studies (two randomized) assessed the hemodynamic effects of the beta1-blocker esmolol.	esmolol	96-103	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	82-87	
23902616-5	2013	The adrenergic beta-1 antagonist esmolol was injected through central venous catheter to reduce heart rate by 20% from baseline.	esmolol	33-40	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	15-21	
19122550-1	2009	BACKGROUND AND OBJECTIVE: It is known that esmolol, a short-acting beta1-blocker, reduces anaesthetic requirement.	esmolol	43-50	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	67-72	
7502643-5	1995	Selective beta 1 antagonists (i.e., esmolol) may need to be titrated with a direct vasodilator (i.e., nitroprusside) to manage hypertension and tachycardia.	esmolol	36-43	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	10-16	
12197593-1	2002	In recent years there has been renewed interest in beating heart surgery using the ultra-active and selective beta1-blocker, esmolol.	esmolol	125-132	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	110-115	
11602813-2	2001	Celiprolol is a beta 1 -receptor blocker with vasodilating properties, whereas esmolol is an ultra-short-acting beta 1 -blocker.	esmolol	79-86	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	112-118	
16215384-1	2005	OBJECTIVE: Since beta-blocker therapy is known to be effective in patients with an injured heart, such as infarction, we designed the present study to examine the protective effects of infusion of the beta1-selective blocker esmolol on myocardial function in peritonitis-induced septic rats using an isolated working heart preparation.	esmolol	225-232	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	201-206	
12460877-3	2002	METHODS AND RESULTS: We investigated the consequences of short-term intravenous administration of an alpha-1 adrenergic agonist, phenylephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years.	esmolol	180-187	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	150-156	
12565117-4	2002	We concluded that the beta(1) selective, ultra-short acting beta-blocker, esmolol, can be used intraoperatively when both conditions are present.	esmolol	74-81	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	22-29	
7957532-2	1994	Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol.	esmolol	28-35	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	88-94	
7957532-2	1994	Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol.	esmolol	28-35	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	201-207	
1688693-3	1990	Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation.	esmolol	0-7	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	30-36